Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · IEX Real-Time Price · USD
25.26
-0.18 (-0.71%)
Jul 2, 2024, 10:18 AM EDT - Market open
Rapport Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
893.61M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRAPP News
- 19 days ago - Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement - GlobeNewsWire
- 24 days ago - J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut - Reuters
- 25 days ago - J&J-backed Rapport Therapeutics raises $136 mln in US IPO - Reuters
- 25 days ago - Rapport Therapeutics Announces Pricing of Initial Public Offering - GlobeNewsWire
- 4 weeks ago - J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO - Reuters
- 6 weeks ago - J&J-backed startup Rapport files for US IPO - Reuters
- 6 weeks ago - CNS disorder biotech Rapport Therapeutics files for a $100 million IPO - Renaissance Capital
- 6 weeks ago - Rapport Therapeutics IPO Registration Document (S-1) - SEC